Pharvaris BV (PHVS NASDAQ) stock market data APIs
$34.188
0.58(1.7%)
as of November 4, 2026
Try our APIs with
free plan!
Pharvaris BV Financial Data Overview
Price chart is built with
Anychart
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.
Prev. Close
34.188
Open
34.7649
High
35.2092
Low
33.3245
52 wk Range
21.02-43.25
Market Cap
2 442 M
Shares Outstanding
70 205 K
EPS
-0.81
Beta
-2.517
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Pharvaris BV (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Pharvaris BV data using free add-ons & libraries
Get Pharvaris BV Fundamental Data
Pharvaris BV Fundamental data includes:
- Net Revenue:
- EBITDA: -182 166 128
- Earnings Per Share: -3
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-08-12
- EPS/Forecast: -0.74
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Pharvaris BV News
New
BioCryst (BCRX) Trades at Just 11x Forward Earnings. Is the Market Pricing In Trouble?
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) has reached a financial milestone that many smaller biotechnology companies never reach: an approved treatment is generating recurring revenue and supporti...
PHVS Stock Rises 10% in a Month: What Is Driving the Rally?
Shares of Pharvaris PHVS have gained 10% over the past month, due to the positive top-line data announced on Sept. 8, 2026, from the pivotal phase III CHAPTER-3 study, which evaluated its lead drug ca...
BioCryst Pharmaceuticals Faces Competitive Pressure in Hereditary Angioedema Treatment, RBC Says
BioCryst Pharmaceuticals' (BCRX) Ordaleyo faces competitive pressure in the hereditary angioedema tr PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscri...
Stocks Settle Lower on Middle East Jitters
The S&P 500 Index ($SPX) (SPY) closed down -0.58% on Tuesday, the Dow Jones Industrial Average ($DOWI) (DIA) closed down -1.18%, and the Nasdaq 100 Index ($IUXX) (QQQ) closed down -0.12%. E-mini...
Get Pharvaris BV fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
Best Offer
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.